Monoclonal antibody and application thereof in preparation of reagent for detecting camptothecin compound and protein compound

By providing monoclonal antibodies with specific amino acid sequences in the CDR region, the problem of insufficient sensitivity and specificity of detection of camptothecin compounds and protein complexes in the prior art is solved, and efficient recognition of MF6 and protein complexes is achieved and Test.

CN119080939APending Publication Date: 2024-12-06JIANGSU MABWELL HEALTH PHARMA R&D CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410724403.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-06
Filing Date
2024-06-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to provide excellent performance monoclonal antibodies for detecting camptothecin-like compounds and protein complexes, especially when identifying MF6-protein complexes in biological samples, lacking high sensitivity and specificity.

Method used

A monoclonal antibody is provided with a specific sequence identity of the amino acid sequence of the CDR region of the light and heavy chains, capable of specifically identifying a complex formed by camptothecin or its derivatives with proteins, especially MF6 and BSA or HER2. The complex has good affinity and is used to prepare detection reagents to improve detection effect.

Benefits of technology

Accurate detection of camptothecin-like compounds and protein complexes, providing higher sensitivity and specificity, and can accurately identify MF6-antibody-binding drug levels and complex stability in biological samples, compared with other antibodies Shows better recognition effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004878166760000121
    Figure BDA0004878166760000121
  • Figure BDA0004878166760000122
    Figure BDA0004878166760000122
  • Figure BDA0004878166760000141
    Figure BDA0004878166760000141
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, in particular to a monoclonal antibody and application thereof in preparation of a reagent for detecting a camptothecin compound and a protein compound. The monoclonal antibody provided by the invention is a monoclonal antibody targeting a camptothecin compound and protein compound, especially can specifically recognize the compound formed by the camptothecin compound and protein, shows good affinity, can also realize quantitative detection on ADC with a low drug-antibody coupling ratio, and has good application prospects. The method can be used for accurate detection of ADC macromolecules taking camptothecin compounds as toxins in biological samples.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of the Chinese patent application filed with the China Patent Office on June 6, 2023, with application number 202310665970.2 and invention name “Monoclonal antibodies and their use in the preparation of reagents for detecting camptothecin compounds and protein complexes”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present invention relates to the field of biomedicine technology, and in particular to a monoclonal antibody and an application thereof in preparing a reagent for detecting a camptothecin compound and a protein complex. Background Art

[0003] Camptothecin (CPT) is a cytotoxic quinoline alkaloid that selectively inhibits topoisomerase I (TopoⅠ). The complex formed with topoisomerase I and DNA can cause single-strand breaks in DNA, prevent DNA replication, and inhibit RNA synthesis. Topoisomerase I is highly expressed in a variety of tumor cells such as colon cancer, cervical cancer, and ovarian cancer, with a content much higher than that in normal tissues or cells, and its activity is greatly increased in S-phase tumor cells. Therefore, active inhibitors of topoisomerase I can selectively inhibit DNA replication in proliferating tumor cells. Experiments have shown that camptothecin has an inhibitory effect on a variety of animal tumors, has no cross-resistance with commonly used anti-tumor drugs, and is used as an anti-tumor drug in clinical practice. In addition, camptothecin and various derivatives are also under continuous development.

[0004] MF6 is a camptothecin derivative that also acts as a DNA topoisomerase I inhibitor. The MF6 small molecule can be used as the cytotoxic component of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. ADCs enter cells through target-mediated endocytosis. In lysosomes, the ADCs are cut off from the linker by cathepsins, releasing toxic small molecules to specifically kill tumor cells while avoiding damage to normal cells.

[0005] In order to further study the pharmacokinetics or immunogenicity of the complexes of camptothecin compounds and proteins, it is usually necessary to detect the content and distribution of camptothecin or its derivatives in the body. Immunological detection is a commonly used detection method in this field. In order to achieve good detection of the complexes of camptothecin compounds and proteins, antibodies with good performance are needed to prepare detection reagents. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide a monoclonal antibody and its application in preparing a reagent for detecting a complex of a camptothecin compound and a protein.

[0007] The monoclonal antibody provided by the present invention comprises a light chain and a heavy chain.

[0008] The light chain comprises three CDR regions, wherein the amino acid sequence of at least one of the CDR regions has an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 9, or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto; and

[0009] The heavy chain comprises three CDR regions, wherein the amino acid sequence of at least one of the CDR regions has an amino acid sequence as shown in any one of SEQ ID NOs: 10 to 18 or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0010] In some embodiments,

[0011] The three CDR regions of the light chain have the amino acid sequences shown in any one of SEQ ID NOs: 1 to 9, respectively; the three CDR regions of the heavy chain have the amino acid sequences shown in any one of SEQ ID NOs: 10 to 18, respectively. For example, in the monoclonal antibody,

[0012] Its light chain CDR1 has an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 3;

[0013] Its light chain CDR2 has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 6;

[0014] The light chain CDR3 thereof has an amino acid sequence as shown in any one of SEQ ID NOs: 7 to 9.

[0015] In some specific embodiments,

[0016] The amino acid sequence of CDR1 in the antibody light chain is:

[0017] RASGNIHNFLA (SEQ ID NO: 1),

[0018] RASGDIHNYLA (SEQ ID NO: 2)

[0019] or QASQSVYDNKKWS (SEQ ID NO: 3);

[0020] The amino acid sequence of CDR2 in the antibody light chain is:

[0021] NAYTLAD (SEQ ID NO: 4),

[0022] YAKTLAD (SEQ ID NO: 5),

[0023] or DASTLAS (SEQ ID NO: 6);

[0024] The amino acid sequence of CDR3 in the antibody light chain is:

[0025] QHFWNTPYT (SEQ ID NO: 7),

[0026] QHFLSTPYT (SEQ ID NO: 8),

[0027] or TGGFTGDPYVA (SEQ ID NO: 9).

[0028] For example, in the monoclonal antibody,

[0029] Its heavy chain CDR1 has an amino acid sequence as shown in any one of SEQ ID NOs: 10 to 12;

[0030] Its heavy chain CDR2 has an amino acid sequence as shown in any one of SEQ ID NOs: 13 to 15;

[0031] The heavy chain CDR3 thereof has an amino acid sequence as shown in any one of SEQ ID NOs: 16-18.

[0032] In some specific embodiments,

[0033] The amino acid sequence of CDR1 in the antibody heavy chain is:

[0034] NYFMH (SEQ ID NO: 10),

[0035] SYWMH (SEQ ID NO: 11),

[0036] or DYWMT (SEQ ID NO: 12);

[0037] The amino acid sequence of CDR2 in the antibody heavy chain is:

[0038] YIDPYNDVTKYNEKFKGK(SEQ ID NO:13)、NIYLGSGSVNYDEKFKS(SEQ ID NO:14)、

[0039] or VINSRGNTFYASWANG (SEQ ID NO: 15);

[0040] The amino acid sequence of CDR3 in the antibody heavy chain is:

[0041] WDGNNGY (SEQ ID NO: 16),

[0042] YHLNYGGY (SEQ ID NO: 17),

[0043] or GAWTTDI (SEQ ID NO: 18).

[0044] In some specific embodiments, in the monoclonal antibody,

[0045] Its light chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NOs: 1, 4, and 7, respectively;

[0046] or its light chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NOs: 2, 5, and 8, respectively;

[0047] Or its light chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NOs: 3, 6, and 9, respectively.

[0048] In some specific embodiments, in the monoclonal antibody,

[0049] Its heavy chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NOs: 10, 13, and 16, respectively,

[0050] or its heavy chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NO: 11, 14, 17 in sequence,

[0051] Or its heavy chain CDR1 to 3 have the amino acid sequences shown in SEQ ID NO: 12, 15, and 18, respectively.

[0052] More specifically, in the monoclonal antibody,

[0053] The amino acid sequences of its light chain CDR1 to 3 are shown in SEQ ID NOs: 1, 4, and 7, respectively, and the amino acid sequences of its heavy chain CDR1 to 3 are shown in SEQ ID NOs: 10, 13, and 16, respectively;

[0054] or the amino acid sequences of its light chain CDR1 to 3 are shown in SEQ ID NOs: 2, 5, and 8, respectively, and the amino acid sequences of its heavy chain CDR1 to 3 are shown in SEQ ID NOs: 11, 14, and 17, respectively;

[0055] Or the amino acid sequences of its light chain CDR1-3 are shown in SEQ ID NOs: 3, 6, and 9, respectively, and the amino acid sequences of its heavy chain CDR1-3 are shown in SEQ ID NOs: 12, 15, and 18, respectively.

[0056] In the monoclonal antibody of the present invention,

[0057] The light chain comprises four FR regions, wherein the amino acid sequence of at least one of the FR regions has an amino acid sequence as shown in any one of SEQ ID NOs: 19 to 30, or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto; and

[0058] The heavy chain comprises four FR regions, wherein the amino acid sequence of at least one of the FR regions has an amino acid sequence as shown in any one of SEQ ID NOs: 31 to 42, or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0059] In some embodiments,

[0060] The four FR regions of the light chain have the amino acid sequence shown in any one of SEQ ID NOs: 19 to 30 respectively;

[0061] The four FR regions of the heavy chain have the amino acid sequence shown in any one of SEQ ID NOs: 31 to 42, respectively.

[0062] Specifically, in the monoclonal antibody:

[0063] Its light chain FR1 has an amino acid sequence as shown in any one of SEQ ID NOs: 19 to 21;

[0064] Its light chain FR2 has an amino acid sequence as shown in any one of SEQ ID NOs: 22 to 24;

[0065] Its light chain FR3 has an amino acid sequence as shown in any one of SEQ ID NOs: 25 to 27;

[0066] The light chain FR4 thereof has an amino acid sequence as shown in any one of SEQ ID NOs: 28-30.

[0067] In some specific embodiments,

[0068] The amino acid sequence of FR1 in the antibody light chain is:

[0069] DIQMTQSPASLSSASVGETVTITC(SEQ ID NO:19)、

[0070] DIQMTQSPASLSSASVGETVTITC(SEQ ID NO:20)

[0071] or QVLTQTPSSVSAPVGGTVTINC (SEQ ID NO: 21);

[0072] The amino acid sequence of FR2 in the antibody light chain is:

[0073] WYQQKQGKSPQLLVY(SEQ ID NO:22)、

[0074] WYQQKQGKSPQVLVY (SEQ ID NO: 23) or

[0075] WYQKKPGQPPKLLIY(SEQ ID NO:24);

[0076] The amino acid sequence of FR3 in the antibody light chain is:

[0077] GVPSRFSGSGSGTQYSLKINSLQPEDFGSYYC(SEQ ID NO:25),GVPSRFSGSGSGTQYSLKINSLQPEDFGTYYC(SEQ ID NO:26)

[0078] orGVSSRFRGSGSGTQFTLTIRDLECDDGATYYC(SEQ ID NO:27);

[0079] The amino acid sequence of FR4 in the antibody light chain is:

[0080] FGGGTRLEIKRA (SEQ ID NO: 28),

[0081] FGGGTTLEIKRA (SEQ ID NO: 29),

[0082] or FGGGTEVVVK (SEQ ID NO: 30).

[0083] Specifically, in the monoclonal antibody:

[0084] Its heavy chain FR1 has an amino acid sequence as shown in any one of SEQ ID NOs: 31 to 33;

[0085] Its heavy chain FR2 has an amino acid sequence as shown in any one of SEQ ID NOs: 34 to 36;

[0086] Its heavy chain FR3 has an amino acid sequence as shown in any one of SEQ ID NOs: 37 to 39;

[0087] The heavy chain FR4 thereof has an amino acid sequence as shown in any one of SEQ ID NOs: 40-42.

[0088] In some specific embodiments,

[0089] The amino acid sequence of FR1 in the antibody heavy chain is:

[0090] EVQLQQSGPELVKPGASVKMSCKASGNTFS (SEQ ID NO:31), QVQLQQPGSELVRPGASVKLSCKASGYTFT (SEQ ID NO:32), or QSLEESGGRLVTPGTPLTLTCTASGFSLS (SEQ ID NO:33);

[0091] The amino acid sequence of FR2 in the antibody heavy chain is:

[0092] WVKQKPGQGLEWIG(SEQ ID NO:34)、

[0093] WVKQRPGQGLEWIG(SEQ ID NO:35)、

[0094] or WVRQAPGKGLEFIG (SEQ ID NO: 36);

[0095] The amino acid sequence of FR3 in the antibody heavy chain is:

[0096] ATLTSDKSSNTAYMELSILTSEDSAVYYCTR (SEQ ID NO:37), KATLTADTSSSTAYMQLSSLTPEDSAVYYCTA (SEQ ID NO:38), or RFTISKTSTTVDLKMTSLTAADTATYFCGR (SEQ ID NO:39);

[0097] The amino acid sequence of FR4 in the antibody heavy chain is:

[0098] WGQGTTLVVSS (SEQ ID NO: 40),

[0099] WGQGTTLTVSS (SEQ ID NO: 41),

[0100] or WGPGTLVTVSS (SEQ ID NO: 42).

[0101] More specifically, in the monoclonal antibody,

[0102] Its light chain FR1-4 has the amino acid sequences shown in SEQ ID NOs: 19, 22, 25, and 28, respectively;

[0103] or its light chain FR1-4 have the amino acid sequences shown in SEQ ID NOs: 20, 23, 26, and 29, respectively;

[0104] Or its light chain FR1-4 have the amino acid sequences shown in SEQ ID NO: 21, 24, 27, 30 in sequence.

[0105] More specifically, in the monoclonal antibody,

[0106] Its heavy chain FR1 to 4 have the amino acid sequences shown in SEQ ID NOs: 31, 34, 37, and 40, respectively, or its heavy chain FR1 to 4 have the amino acid sequences shown in SEQ ID NOs: 32, 35, 38, and 41, respectively, or its heavy chain FR1 to 4 have the amino acid sequences shown in SEQ ID NOs: 33, 36, 39, and 42, respectively.

[0107] In a specific embodiment, the amino acid sequences of the light chain FR1 to 4 of the monoclonal antibody are shown in SEQ ID NOs: 19, 22, 25, and 28, respectively, and the amino acid sequences of the heavy chain FR1 to 4 are shown in SEQ ID NOs: 31, 34, 37, and 40, respectively;

[0108] In another specific embodiment, the amino acid sequences of the light chain FR1-4 of the monoclonal antibody are shown in SEQ ID NOs: 20, 23, 26, and 29, respectively, and the amino acid sequences of the heavy chain FR1-4 are shown in SEQ ID NOs: 32, 35, 38, and 41, respectively;

[0109] In another specific embodiment, the amino acid sequences of the light chain FR1-4 of the monoclonal antibody are shown in SEQ ID NOs: 21, 24, 27, and 30, respectively, and the amino acid sequences of the heavy chain FR1-4 are shown in SEQ ID NOs: 33, 36, 39, and 42, respectively.

[0110] In some embodiments,

[0111] The C-terminus of the antibody light chain variable region of the present invention is also connected to a signal peptide, which has an amino acid sequence as shown in any one of SEQ ID NOs: 55 to 57 or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0112] The C-terminus of the antibody heavy chain variable region of the present invention is also connected to a signal peptide, which has an amino acid sequence as shown in any one of SEQ ID NOs: 58 to 60 or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0113] In some specific embodiments,

[0114] The light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in any one of SEQ ID NOs: 43 to 45, or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0115] The heavy chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in any one of SEQ ID NOs: 46 to 48, or a sequence having at least 80% (preferably 85%, 90%, 95%, 98% or 99%) sequence identity thereto.

[0116] More specifically, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in any one of SEQ ID NOs: 43 to 45, and the heavy chain variable region has an amino acid sequence as shown in any one of SEQ ID NOs: 46 to 48.

[0117] Furthermore,

[0118] The light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:43, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:46, 47 or 48.

[0119] Alternatively, the light chain variable region of the monoclonal antibody of the present invention has the amino acid sequence shown in SEQ ID NO:44, and the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:46, 47 or 48.

[0120] Alternatively, the light chain variable region of the monoclonal antibody of the present invention has the amino acid sequence shown in SEQ ID NO:45, and the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:46, 47 or 48.

[0121] Alternatively, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:43, 44 or 45, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:46.

[0122] Alternatively, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:43, 44 or 45, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:47.

[0123] Alternatively, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:43, 44 or 45, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:48.

[0124] In a specific embodiment, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:43, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:46.

[0125] In another specific embodiment, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:44, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:47.

[0126] In another specific embodiment, the light chain variable region of the monoclonal antibody of the present invention has an amino acid sequence as shown in SEQ ID NO:45, and the heavy chain variable region thereof has an amino acid sequence as shown in SEQ ID NO:48.

[0127] The monoclonal antibody of the present invention further comprises a constant region, the constant region of the heavy chain is mouse IgG or rabbit IgG, and the constant region of the light chain is κ type. Wherein, the mouse IgG is IgG1.

[0128] The monoclonal antibody provided by the present invention can recognize the complex formed by camptothecin or its derivatives and protein, especially can specifically recognize the complex of MF6 and BSA or HER2 antibody, has good affinity, can be used for detecting the level of MF6-antibody binding drug in biological samples or the stability of antibody binding MF6 complex, and compared with other prepared antibodies, the monoclonal antibody provided by the present invention has a better effect in the process of identifying MF6-antibody binding drug. The reagent prepared by using the antibody can obtain higher sensitivity and specificity.

[0129] The present invention also provides a nucleic acid encoding the monoclonal antibody as described above.

[0130] The nucleic acid of the present invention includes nucleic acid encoding light chain variable region and nucleic acid encoding heavy chain variable region. The nucleic acid may be DNA, RNA, cDNA or PNA. It may be single-stranded or double-stranded. The nucleic acid may include nucleotide sequences with different functions, such as coding regions and non-coding regions such as regulatory sequences (e.g., promoters or transcription terminators). The nucleic acid may be linear or circular in topology. The nucleic acid may be, for example, a part of a vector (e.g., an expression or cloning vector), or a combination of one or more fragments. The nucleic acid may be obtained directly from a natural source, or may be prepared with the assistance of recombination, enzymatic or chemical techniques. The RNA form is mRNA obtained by gene transcription, etc. In some embodiments, the sequence of the nucleic acid encoding the light chain variable region is shown in any one of SEQ ID NOs: 49 to 51; the sequence of the nucleic acid encoding the heavy chain variable region is shown in any one of SEQ ID NOs: 52 to 54.

[0131] Further, the present invention also provides an expression vector comprising a nucleic acid encoding a monoclonal antibody as described above. The source of the vector backbone of the present invention includes plants, animals, bacteria, fungi, phages, or viruses, and the present invention is not limited to this. In some embodiments, the backbone vector of the expression vector is pcDNA3.1, AbVec2.0-hIgG1, pComb3XTT, pComb3, pFUSE-hIgG4-Fc2, pComb3Xlambda, pEE12.4, pEE6.4, pCHO1.0, pComb3XSS, pFUSE-hIgG1e1-Fc2, pcDNA3.1-hIgG1-Fc2, pFUSE-hIgG1-Fc2 or pFUSE-mIgG1-Fc2.

[0132] Furthermore, the present invention also provides a host, whose genome is integrated with a nucleic acid encoding a monoclonal antibody as described above; or transfected or transformed with an expression vector as described above. The host described in the present invention is used for the preservation or amplification of the nucleic acid described in the present invention, and can also be used for the construction and expression of the antibody, which is not limited by the present invention. In some embodiments, the cell is a prokaryotic cell or a eukaryotic cell. In the present invention, the prokaryotic cell or prokaryotic organism includes but is not limited to Escherichia coli, and the eukaryotic cell includes a fungal cell, a plant cell, a mammalian cell or an insect cell, which is selected from yeast, CHO cells, BHK cells, Sp2 / 0, HEK-293, HEK293T, Hep G2, HELA, CHO-K1, COS-1, COS-7, NIH3T3, A204, A549, D-407, CHO, HCS-2, HT-29, U87, Sf9 and at least one of FD-CHOS.

[0133] Furthermore, the present invention also provides a method for preparing the monoclonal antibody as described above, comprising: culturing the host cell and inducing the expression of the monoclonal antibody. The preparation method also includes isolating the antibody or antigen-binding fragment or polypeptide expressed by the cell.

[0134] Furthermore, the present invention also provides a labeled antibody, which is a monoclonal antibody as described above that is chemically labeled or biologically labeled. In the present invention, the chemical label is an isotope, an immunotoxin and / or a chemical drug; the biological label is biotin, avidin or an enzyme label. The enzyme label is preferably horseradish peroxidase or alkaline phosphatase. The immunotoxin is preferably aflatoxin, diphtheria toxin, Pseudomonas aeruginosa exotoxin, ricin, abrin, mistletoe agglutinin, radix fasciatus toxin, PAP, herbivorin, gelonin or luffa toxin.

[0135] Furthermore, the present invention also provides a conjugate obtained by coupling the monoclonal antibody or the labeled antibody as described above with a solid medium or a semi-solid medium. In the present invention, the solid medium or the semi-solid medium is selected from colloidal gold, a polystyrene plate, a 96-well plate, a 48-well plate, a 24-well plate, a 12-well plate, a 6-well plate or beads. Preferably, the beads are magnetic beads, latex microspheres or polystyrene microspheres.

[0136] Furthermore, the present invention also provides the use of any one of the following in the preparation of a detection reagent for a complex of a camptothecin compound and a protein;

[0137] I), monoclonal antibodies as described above;

[0138] II), labeled antibodies as described above;

[0139] III), the conjugate as described above.

[0140] In the present invention, in the camptothecin compound and protein complex, the camptothecin compound is MF6 or MWC-1, and the protein is BSA or an antibody targeting HER2. Furthermore, the present invention also provides a detection reagent for the camptothecin compound and protein complex, which includes any of the following:

[0141] I), monoclonal antibodies as described above;

[0142] II), labeled antibodies as described above;

[0143] III), the conjugate as described above.

[0144] The detection reagent provided by the present invention is a reagent based on immunological detection, which also includes an ELISA plate, a detection antibody, a blocking solution, a sample diluent, a flushing solution and a color developing solution;

[0145] Wherein, the detection antibody is a goat anti-human antibody labeled with HRP or a goat anti-rabbit antibody labeled with HRP;

[0146] The blocking solution is PBST buffer containing 3wt% BSA;

[0147] The sample diluent is a PBST buffer containing 1wt% BSA;

[0148] The flushing solution is PBST buffer;

[0149] The color developing solution is TMB solution.

[0150] Furthermore, the present invention also provides a method for detecting a complex of a camptothecin compound and a protein, comprising detecting a sample with the detection reagent.

[0151] In the present invention, the detection includes the detection of the content of the camptothecin compound-antibody conjugate drug in plasma, and / or the stability detection of the camptothecin compound-antibody conjugate drug. The camptothecin compound is MF6 or MWC-1, and the antibody is a HER2 antibody. Preferably, the DAR value of the camptothecin compound-antibody conjugate drug is in the range of 1-8, preferably 1-4.

[0152] The detection method described in the present invention is a detection for non-diagnostic purposes, and is mainly used in pharmacokinetic analysis and immunogenicity analysis of antibody-drug conjugates.

[0153] The present invention provides monoclonal antibodies and their use in preparing reagents for detecting camptothecin compounds and protein complexes or camptothecin compounds. The monoclonal antibodies provided by the present invention are monoclonal antibodies targeting camptothecin compounds and protein complexes, and in particular can specifically recognize the complexes formed by camptothecin compounds and proteins, showing good affinity, and can be used for accurate detection of ADC macromolecules with camptothecin compounds as toxins in biological samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0154] The technical solution of the present invention is further described below in conjunction with the accompanying drawings:

[0155] Figure 1 The standard curves of three camptothecin compound-protein complexes or camptothecin compound monoclonal antibodies applied to the quantitative detection of Trastuzumab ADC concentration are shown (S-22-11, S-140-9, 45G1-1);

[0156] Figure 2 The standard curve of drug concentration-time variation of MF6-conjugated ADC is shown (S-22-11);

[0157] Figure 3 The standard curve of drug concentration-time variation of MF6-conjugated ADC (45G1-1) is shown. DETAILED DESCRIPTION

[0158] The present invention provides monoclonal antibodies and their use in the preparation of reagents for detecting camptothecin compounds and protein complexes or camptothecin compounds. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0159] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0160] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural.

[0161] In this application, "at least one" means one or more, "more than one" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single or plural items.

[0162] Furthermore, unless otherwise indicated herein, singular terms shall include pluralities and plural terms shall include the singular. More specifically, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly indicated otherwise.

[0163] The terms "include", "comprising" and "having" are used interchangeably herein and are intended to indicate the inclusiveness of the solution, meaning that the solution may have other elements in addition to the listed elements. At the same time, it should be understood that the use of "include", "comprising" and "having" descriptions herein also provides a "consisting of..." solution.

[0164] The term "and / or" when used herein includes the meanings of "and", "or" and "all or any other combination of elements linked by the term".

[0165] "Antibody" refers to a protein composed of one or more polypeptides that can specifically bind to an antigen. One form of antibody constitutes the basic structural unit of an antibody. This form is a tetramer, which is composed of two identical pairs of antibody chains, each pair having a light chain and a heavy chain. In each pair of antibody chains, the variable regions of the light chain and the heavy chain are jointly responsible for binding to the antigen, while the constant region is responsible for the effector function of the antibody. The "monoclonal antibody" refers to a preparation of antibody molecules with a single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a specific epitope.

[0166] The "antibody" encompasses various forms and various structures, as long as they exhibit the desired antigen binding activity. The "CDR region" or "CDR" refers to the hypervariable region of the heavy and light chains of immunoglobulins, as defined by Kabat et al. (Kabat et al., Sequences of proteins of immunological interest, 5th Ed., USDepartment of Health and Human Services, NIH, 1991, and later versions). There are three heavy chain CDRs and three light chain CDRs. Depending on the circumstances, the term CDR or CDRs used herein is to indicate one of these regions, or several or even all of these regions, which contain most of the amino acid residues responsible for binding through the affinity of the antibody to the antigen or its recognition epitope.

[0167] The "antibody" includes a typical "four-chain antibody", which is an immunoglobulin composed of two heavy chains (HC) and two light chains (LC); the heavy chain refers to a polypeptide chain, which is composed of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain in the direction from N-terminus to C-terminus; and, when the full-length antibody is an IgE isotype, it optionally also includes a heavy chain constant region CH4 domain; the light chain is a polypeptide chain composed of a light chain variable region (VL) and a light chain constant region (CL) in the direction from N-terminus to C-terminus; the heavy chains and the heavy chains, and the heavy chains and the light chains are connected by disulfide bonds to form a "Y"-shaped structure.

[0168] The "variable region" refers to the region of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen, and "heavy chain variable region" is used interchangeably with "VH" and "HCVR", and "light chain variable region" is used interchangeably with "VL" and "LCVR". The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity. The terms "complementarity determining region" and "CDR" are used interchangeably herein, and usually refer to the hypervariable region (HVR) of the heavy chain variable region (VH) or the light chain variable region (VL). This part is also called the complementarity determining region because it can form precise complementarity with the antigen epitope in terms of spatial structure. Among them, the heavy chain variable region CDR can be abbreviated as HCDR, and the light chain variable region CDR can be abbreviated as LCDR. The terms "framework region" or "FR region" are interchangeable and refer to those amino acid residues other than CDR in the heavy chain variable region or light chain variable region of an antibody. Usually, a typical antibody variable region consists of 4 FR regions and 3 CDR regions in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0169] The "heavy chain constant region" refers to the carboxyl terminal part of the antibody heavy chain, which is not directly involved in the binding of the antibody to the antigen, but exhibits effector functions, such as interactions with Fc receptors, and has a more conservative amino acid sequence relative to the variable domain of the antibody. The "heavy chain constant region" can be selected from: CH1 domain, hinge region, CH2 domain, CH3 domain, or variants or fragments thereof. The "heavy chain constant region" includes a "full-length heavy chain constant region" and a "heavy chain constant region fragment", the former having a structure substantially similar to that of a natural antibody constant region, while the latter only includes "a portion of the full-length heavy chain constant region". Exemplarily, a typical "full-length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain antibody, it does not include a CH1 domain. Exemplarily, a typical "heavy chain constant region fragment" can be selected from an Fc or CH3 domain.

[0170] The “light chain constant region” refers to the carboxyl terminal portion of the antibody light chain, which is not directly involved in the binding of the antibody to an antigen, and the light chain constant region can be selected from a constant kappa domain or a constant lambda domain.

[0171] Since the amino acid composition and arrangement order of the constant region of the heavy chain of immunoglobulin are different, their antigenicity is also different. Based on this, the "immunoglobulin" in this article can be divided into five categories, or called immunoglobulin isotypes, namely IgM, IgD, IgG, IgA and IgE, and their corresponding heavy chains are μ chain, δ chain, γ chain, α chain and ε chain. The same type of Ig can be divided into different subclasses according to the difference in the amino acid composition of its hinge region and the number and position of the disulfide bonds of the heavy chain, such as IgG can be divided into IgG1, IgG2, IgG3, IgG4, and IgA can be divided into IgA1 and IgA2. The light chain is divided into κ chain or λ chain by the difference in the constant region. Each of the five types of Ig can have κ chain or λ chain.

[0172] The term "specific binding" means that an antigen-binding molecule (e.g., an antibody) typically binds specifically to an antigen and substantially the same antigen with high affinity, but does not bind to unrelated antigens with high affinity. Affinity is typically reflected by an equilibrium dissociation constant (KD), where a lower KD indicates a higher affinity. Taking antibodies as an example, a high affinity typically refers to a specific affinity of about 10 -6 M or lower, about 10 -7 M or lower, about 10 -8 M or less, about 1×10 -9 M or less, about 1×10 -10 M or less, 1×10 -11 M or less or 1×10 -12 The KD is calculated as follows: KD = Kd / Ka, where Kd represents the dissociation rate and Ka represents the association rate. The equilibrium dissociation constant KD can be measured by methods well known in the art, such as surface plasmon resonance (e.g., Biacore) or equilibrium dialysis.

[0173] In the present invention, "antibodies" can be derived from any animal, including but not limited to humans and non-human animals, and the non-human animals can be selected from primates, mammals, rodents and vertebrates, such as camelids, llamas, ostriches, alpacas, sheep, rabbits, mice, rats or cartilaginous fish (such as sharks).

[0174] The term "identity" herein can be calculated in the following manner: to determine the percentage of "identity" of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal comparison or non-homologous sequences can be discarded for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, the molecules are identical at this position.

[0175] The percent identity between the two sequences will vary depending on the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0176] The term "nucleic acid" herein includes any compound and / or substance comprising a polymer of nucleotides. Each nucleotide is composed of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose) and a phosphate group. Typically, nucleic acid molecules are described by a sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is typically expressed as 5' to 3'. In this article, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and polymers comprising a mixture of two or more of these molecules. Nucleic acid molecules can be linear or cyclic. In addition, the term nucleic acid molecule includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Moreover, nucleic acid molecules as described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derived sugar or phosphate backbone bonding or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules, which are suitable as carriers for direct expression of antibodies of the present invention in vitro and / or in vivo, such as in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA may be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoded molecule, so that mRNA may be injected into a subject to produce antibodies in vivo (see, e.g., Stadler et al., Nature Medicine 2017, published online June 12, 2017, doi: 10.1038 / nm.4356 or EP 2 101 823B1). "Isolated" nucleic acid herein refers to a nucleic acid molecule that has been separated from the components of its natural environment. Isolation nucleic acid includes a nucleic acid molecule contained in the following cells, which typically contains the nucleic acid molecule, but the nucleic acid molecule is present outside the chromosome or at a chromosomal position different from its natural chromosomal position.

[0177] The term "vector" or "expression vector" herein refers to a nucleic acid molecule capable of amplifying another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which the vector has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."

[0178] The term "host cell" or "host" herein refers to a cell into which an exogenous nucleic acid is introduced, including the offspring of such a cell. Host cells include "transformants" and "transformed cells", which include primary transformed cells and offspring derived therefrom, without considering the number of passages. Offspring may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. Mutant offspring having the same function or biological activity as screened or selected in the initially transformed cell are included herein.

[0179] The term "camptothecin compound and protein complex" herein may also be referred to as "camptothecin compound and protein-bound drug", or "protein-drug conjugate", wherein the camptothecin compound is, for example, MF6 or MWC-1, and the protein is, for example, an antibody or albumin. In one embodiment, the antibody is a HER2 antibody. When the protein is an antibody, it is also referred to as a camptothecin compound-antibody-bound drug.

[0180] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0181] The present invention will be further described below in conjunction with embodiments:

[0182] Example 1

[0183] 1. Preparation process of anti-MWC-1 mouse monoclonal antibody

[0184] 1. Preparation of immunogens: KLH (hemocyanin) and OVA (ovalbumin) were coupled to the MWC-1 small molecule shown in Formula I via free thiol groups to prepare KLH-MWC-1 and OVA-MWC-1 samples, respectively. The specific preparation methods are as follows:

[0185] 1) Preparation of KLH and OVA solution:

[0186] Dissolve KLH and OVA solids in 50 mmol / L PB, pH 6.5 buffer solution to prepare KLH and OVA solutions at concentrations of 10 ± 5 mg / ml, respectively;

[0187] 2) Preparation of SMCC solution: Weigh a certain amount of SMCC ((N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester) small molecule, dissolve it in DMA (N,N-dimethylacetamide) to prepare a 10 mg / ml SMCC solution. SMCC is a bifunctional coupling agent containing N-hydroxysuccinimide (NHS) active ester and maleimide;

[0188] 3) Add SMCC solution to the above KLH and OVA reaction solution, react for 15 minutes, and then replace the solution by ultrafiltration;

[0189] 4) Preparation of MWC-1 solution:

[0190] A certain amount of MWC-1 powder with a connector was weighed and dissolved in DMA to prepare a 10 mg / ml MWC-1 solution with a connector.

[0191] 5) DMA (7%-8% of the total volume of the solution) was pre-added to the solution in 3) and mixed well, followed by addition of the prepared MWC-1 solution with a linker, with the molar ratio of KLH and OVA to MWC-1 being ≥3. The mixture was reacted at 25±5°C for 1.5 h.

[0192] 6) Ultrafiltration to remove free MWC-1 small molecules with linkers and DMA residues:

[0193] Ultrafiltration centrifuge tubes (Milipore / 30K) were used to centrifuge and replace the liquid with 50mmol / LPB, pH 6.5 buffer solution, and the replacement volume was ≥1000 times to remove free MWC-1 small molecules with a linker and DMA residues. The centrifuged liquid samples were collected, 6% trehalose was added, and the dissolved samples were filtered with a 0.2μm filter membrane to obtain KLH-MWC-1 and OVA-MWC-1 samples.

[0194] 2. Animal immunization: Use KLH and OVA-coupled MWC-1 samples to immunize 5 Balb / c mice, 3 times per mouse, each cycle is 3 weeks. The immunized mouse serum should have specific binding with the corresponding immunogen, and the antiserum titer should be above 1:10,000.

[0195] 3. Hybridoma screening: Select spleen cells from 1-2 mice with the highest titer among the immunized mice and start fusing with SP2 / 0 myeloma cells. During screening, take the culture supernatant from the same well and detect it with MWC-1 coupled with another unrelated carrier protein. Amplify and culture hybridoma cells, take the supernatant to detect ELISA titer and antibody subtype, and select cells that are positive for the corresponding antigen for cloning. In order to ensure the positive rate of the hybridoma cell line and the stable production of antibodies, 3-4 clones are performed, with an interval of 1-2 weeks between each clone. After 3-4 clones are 100% positive, antibody-specific hybridoma cells are obtained.

[0196] 4. Antibody preparation: Mouse monoclonal antibodies are obtained by purification of ascites from immune animals or recombinant expression through hybridoma gene sequencing.

[0197]

[0198] Table 1 ELISA method to detect the titer of MWC-1 mouse monoclonal hybridoma supernatant

[0199]

[0200] Total RNA was extracted from cells and reverse transcribed to obtain cDNA. PCR amplification was performed to obtain the heavy chain and light chain variable region genes of the antibody, which were sequenced and analyzed by bioinformatics to eliminate non-functional antibody genes. The antibodies were named according to the cell clones from which they were derived. The amino acid sequences of the heavy and light chains and their variable regions and CDRs (defined according to the KABAT naming system) are as follows:

[0201] 1. Anti-MWC-1 mouse monoclonal antibody (S-22-11)

[0202] Heavy chain variable region nucleotide sequence

[0203] atggaatggagttggatatttctctttctcctgtcaggaactgcaggtgtccattctgaggtccagctgcagcagtctggacctgagctggtaaagcctggg gcttcagtgaagatgtcctgcaaggcttctggaaacacattcagtaactattttatgcactgggtgaaacagaagcctgggcagggccttgagtggattgga tatattgatccttacaatgatgttactaagtacaatgagaagttcaaaggcaaggccacactgacttcagacaaatcctccaacacagcctacatggagctcagcattctgacctctgaggactctgcggtctattactgtacaaggtggggatggtaacaacggctactggggccaaggcaccactctcgtagtctcctcataa

[0204] Heavy chain variable region amino acid sequence

[0205] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0206] MEWSWIFLFLLSGTAGVHS EVQLQQSGPELVKPGASVKMSCKASGNTFS NYFMH WVKQKPGQGLEWIG YIDPYNDVTKYNEKFKGK ATLTSDKSSNTAYMELSILTSEDSAVYYCTR WDGNNGY WGQGTTLVVSS

[0207] Light chain variable region nucleotide sequence

[0208] atgagtgtgctcactcaggtcctggcgttgctgctgctgtggcttacaggtgccagatgtgacatccagatgactcagtctccagcctccctatctgcatctgtgggagaaactgtcaccatcacatgtcgagcaagtgggaatattcacaaattttttagcttggtatcagcagaaacagggaaaatctcctc agctcctggtctataatgcatacaccttagcagatggtgtgccatcaaggttcagtggcagtggatcaggaacacaatattctctcaagatcaacagcctgcagcctgaagattttgggagttatattactgtcaacatttttggaatactccgtacacgttcggaggggggaccaggctggaaataaaacgggct

[0209] Light chain variable region amino acid sequence

[0210] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0211] MSVLTQVLALLLLWLTGARC DIQMTQSPASLSASVGETVTITC RASGNIHNFLA WYQQKQGKSPQLLVY NAYTLAD GVPSRFSGSGSGTQYSLKINSLQPEDFGSYYC QHFWNTPYT FGGGTRLEIKRA

[0212] 2. Anti-MWC-1 mouse monoclonal antibody (S-140-9)

[0213] Heavy chain variable region nucleotide sequence

[0214] atgggatggagctctatcatcctcttcttggtagcaacagcctcaggtgtccactcccaggtccaactgcagcaacctgggtctgagctggtgaggcctggagcttcagtgaagctgtcctgcaaggcttctggctacacattcaccagctactggatgcactgggtgaaacagaggcctggacaaggccttgagtggataggaaatatttatcttggtagtggtagtgttaactacgatgagaagttcaagagcaaggccacactgactgcagacacatcctccagcacagcctacatgcagctcagcagcctgacacctgaggactctgcggtctattactgcacggcctaccatcttaactacgggggctactggggccaaggcaccactctcacagtctcctca

[0215] Amino acid sequence of the heavy chain variable region

[0216] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0217] MGWSSIILFLVATASGVHS QVQLQQPGSELVRPGASVKLSCKASGYTFT SYWMH WVKQRPGQGLEWIG NIYLGSGSVNYDEKFKS KATLTADTSSSTAYMQLSSLTPEDSAVYYCTA YHLNYGGY WGQGTTLTVSS

[0218] Nucleotide sequence of the light chain variable region

[0219] atgagtgtgctcactcaggtcctggcgttgctgctgctgtggcttacaggtgccagatgtgacatccagatgactcagtctccagcctccctctctgcatctgtgggagaaactgtcaccatcacatgtcgagcaagtggggatattcacaattatttagcatggtatcagcagaaacagggaaaatctcctc aggtcctggtctattatgcaaaaaccttagcagatggtgtgccatcaaggttcagtggcagtggatcaggaacacaatattctctcaagatcaacag cctgcagcctgaagattttgggacttattactgtcaacattttttgagtactccgtacacgttcggaggggggaccacgctggaaataaaacgggct

[0220] Light chain variable region amino acid sequence

[0221] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0222] MSVLTQVLALLLLWLTGARC DIQMTQSPASLSASVGETVTITC RASGDIHNYLA WYQQKQGKSPQVLVY YAKTLAD GVPSRFSGSGSGTQYSLKINSLQPEDFGTYYC QHFLSTPYT FGGGTTLEIKRA

[0223] 2. Preparation process of anti-MF6-rabbit monoclonal antibody

[0224] 1. Preparation of immunogen and test protein: KLH, OVA and BSA (bovine serum albumin) were coupled to MF6 small molecules (Formula II) through free thiol groups to prepare KLH-MF6, OVA-MF6 and BSA-MF6 samples respectively. The specific preparation methods are as follows:

[0225] 1) Preparation of KLH, OVA and BSA solutions:

[0226] Dissolve KLH, OVA and BSA solids in 50mmol / L PB, pH 6.5 buffer solution to prepare a solution concentration of 10±5mg / ml;

[0227] 2) Preparation of SMCC solution: Weigh a certain amount of SMCC small molecules, dissolve them in DMA, and prepare a 10 mg / ml SMCC solution;

[0228] 3) Add SMCC solution to the above KLH and OVA reaction solution, react for 15 minutes, and then replace the solution by ultrafiltration;

[0229] 4) Preparation of MF6 solution:

[0230] A certain amount of MF6 powder with a linker was weighed and dissolved in DMA to prepare a 10 mg / ml MF6 solution with a linker.

[0231] 5) Pre-add 7-8% of the total volume of DMA to the above 3) solution and BSA solution, respectively, and mix well. Then add the prepared MF6 solution with a linker. The molar ratio of KLH, OVA and BSA to MF6 is ≥3. React at 25±5℃ for 1.5h.

[0232] 6) Ultrafiltration to remove free MF6 small molecules with linkers and DMA residues:

[0233] Ultrafiltration centrifuge tubes (Milipore / 30K) were used to centrifuge and replace the liquid with 50mmol / L PB, pH 6.5 buffer solution, and the replacement volume was ≥1000 times to remove free MF6 small molecules with connectors and DMA residues. The centrifuged liquid samples were collected, 6% trehalose was added, and 0.2μm filter membrane was used to filter to obtain KLH-MF6, OVA-MF6 and BSA-MF6 samples.

[0234] 2. Animal immunization: Use KLH and OVA-coupled MF6 samples to immunize three rabbits, three times each. If the immunized animals can reach the immune response level against the immunogen (OD value>1.0 at a dilution of 1:64,000), select the animals for B cell clone screening.

[0235] 3. B cell clone screening: Collect PBMC from fresh blood of at least 2 rabbits to obtain antigen-positive B cells. Use BSA-coupled MF6 to initially screen positive B cells, and use ADCs with different DAR values ​​to rescreen high-binding B cells.

[0236] 4. Antibody preparation: Select the selected B cells for gene sequencing and recombinant expression to obtain monoclonal antibodies.

[0237]

[0238] 5. Extract total RNA from cells and obtain cDNA through reverse transcription. PCR amplification is used to obtain the heavy chain and light chain variable region genes of the antibody, which are sequenced and analyzed by bioinformatics to eliminate non-functional antibody genes. Antibodies are named according to the cell clones from which they are derived. The amino acid sequences of the heavy chain and light chain and their variable regions and CDRs (defined according to the KABAT naming system) are as follows:

[0239] Anti-MF6 rabbit monoclonal antibody (45G1-1)

[0240] Heavy chain variable region nucleotide sequence

[0241] atggagactgggctgcgctggcttctcctggtcgctgtgctcaaaggtgtccagtgtcagtcgctggaggagtccgggggtcgcctggtcacgcctgg aacacccctgacactcacctgcacagcctctggattctccctcagtgactactggatgacctgggtccgccaggctccagggaaggggctggaattca tcggcgtcattaatagtcgtggtaacacattctacgcgagctgggcgaatggtcgattcaccatctccaaaacctcgaccacggtggatctgaaaatg accagtctgacagccgcggacacggccacctatttctgtggtagaggtgcttggaccacggacatctggggcccaggcaccctggtcaccgtctcctca

[0242] Heavy chain variable region amino acid sequence

[0243] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0244] METGLRWLLLVAVLKGVQC QSLEESGGRLVTPGTPLTLTCTASGFSLS DYWMT WVRQAPGKGLEFIG VINSRGNTFYASWANG RFTISKTSTTTVDLKMTSLTAADTATYFCGR GAWTTDI WGPGTLVTVSS

[0245] Light chain variable region nucleotide sequence

[0246] atggacacgagggcccccactcagctgctggggctcctgctgctctggctcccaggtgccacatttgctcaagtgctgacccagactccatcctccgtg tctgcacctgtgggaggcacagtcaccatcaattgccaggccagtcagagtgtttatgataacaagaaatggtcctggtatcagaagaaaccagggcagc ctcccaaactcctgatctacgatgcatccactctggcatctggggtctcatcgcggttcagaggcagtggatctgggacacagttcactctcaccatcag agacctggagtgtgacgatggtgccacttattactgtacaggcggttttactggtgacccctacgttgctttcggcggagggaccgaggtggtggtcaaa

[0247] Light chain variable region amino acid sequence

[0248] Signal peptide- FR1 -CDR1- FR2 -CDR2- FR3 -CDR3- FR4

[0249] MDTRAPTQLLGLLLLWLPGATFA QVLTQTPSSVSAPVGGTVTINC QASQSVYDNKKWS WYQKKPGQPPK LLY DASTLAS GVSSRFRGSGSGTQFTLTIRDLECDDGATYYC TGGFTGDPYVA FGGGTEVVVK

[0250] Example 2 Transient transfection of mammalian cells to express target antibodies

[0251] The three monoclonal antibodies obtained by screening can be prepared by the traditional mouse ascites method or by using mammalian cells to prepare recombinant antibodies. The method of using mammalian cells to prepare recombinant antibodies is as follows.

[0252] 1. Expression plasmid construction

[0253] By means of full gene synthesis, the nucleotide sequences of the light and heavy chains of the three antibodies (S-22-11, S-140-9, 45G1-1) described above, together with the signal peptide sequence, were inserted into a eukaryotic cell expression plasmid, such as pcDNA3.1. The plasmid was then transferred into Escherichia coli for expansion and extraction for subsequent transfection.

[0254] 2. Transient expression of antibodies in eukaryotic cells and purification

[0255] The light chain and heavy chain plasmids of the three antibodies obtained above were respectively transferred into Expi CHO cells for recombinant expression according to the operating instructions of the Expi CHO expression system kit (Gibco, A29133). 12-14 days after cell transfection, the culture supernatant was taken and purified using a Protein A affinity chromatography column to obtain the target antibodies (S-22-11, S-140-9, 45G1-1), and the purified antibodies can be used for subsequent detection tests.

[0256] Example 3 Binding performance test of anti-MWC-1 mouse monoclonal antibody and anti-MF6 rabbit monoclonal antibody with MF6 small molecule

[0257] Considering the high similarity of the structures of MWC-1 compound and MF6 compound, the two differ only by two fluorine atoms, and the anti-MWC-1 antibody can theoretically bind to MF6. According to our test results, this speculation is also verified, and two anti-MWC-1 mouse monoclonal antibodies can also bind to MF6 well. The Trastuzumab ADC (antibody-coupled MF6 drug targeting HER2) described in the present invention, the antibody used is Trastuzumab (trastuzumab), the toxin is MF6, and the linker is a linker valine-alanine linker (VAlinker, valine-alanine linker) that can be hydrolyzed by protease. It has been determined that the drug-antibody ratio (DAR) of Trastuzumab ADC is 4.0, and it is relatively simple, and no other obvious DAR value ADC components are found.

[0258] 1. Test materials

[0259] Table 2: Material information

[0260]

[0261] 2. Main instruments and equipment

[0262] Table 3 Instruments and equipment

[0263] Name of instrument model serial number factory Multifunctional ELISA reader SpectramaxM5 02-IN010 Molecular Devices

[0264] 3. Experimental steps

[0265] 3.1 Coating: Trastuzumab ADC, BSA-MWC-1, and BSA-MF6 were coated at 4°C overnight, with a coating concentration of 2 μg / mL, 100 μl / well;

[0266] 3.2 Blocking: Wash the plate 3 times with PBST, pat dry, add 3% BSA / PBST solution, and incubate at room temperature for 2 hours;

[0267] 3.3 Sample dilution and addition:

[0268] Anti-MWC-1 mouse monoclonal antibodies (clone number S-22-11, clone number S-140-9) were diluted to 100 ng / ml with 1% BSA / PBST, and then diluted 3-fold in sequence to a total of 8 concentrations.

[0269] Anti-MF6 rabbit monoclonal antibody (clone 45G1-1) was diluted to 100 ng / ml with 1% BSA / PBST, and then diluted 2-fold in sequence to a total of 8 concentrations.

[0270] After washing the plate three times with PBST and patting it dry, the above samples were added to the ELISA plate at 100 μl / well and incubated at room temperature for 2 h;

[0271] 3.4 Add secondary antibody: Wash the plate 4 times with PBST and pat dry. Dilute goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP with 1% BSA / PBST at 1:10000, add 100 μl / well to the corresponding ELISA plate, and incubate at room temperature for 1 hour;

[0272] 3.5 Color development: Wash the plate three times with PBST and pat dry. Add TMB substrate to the ELISA plate at 100 μl / well and incubate at room temperature in the dark for about 10 minutes.

[0273] 3.6 Termination: Add 100 μl / well of 1M H3PO4 to terminate the reaction;

[0274] 3.7 Plate reading: After terminating the color development reaction, use 650nm as the reference wavelength and read the OD value at 450nm.

[0275] 3.3 Test results

[0276] The results are shown in Tables 4 and 5. Anti-MWC-1 mouse monoclonal antibody (S-22-11), anti-MWC-1 mouse monoclonal antibody (S-140-9) and anti-MF6 rabbit monoclonal antibody (45G1-1) can all effectively bind to the MF6 small molecule.

[0277] Table 4 Binding results of MWC-1 mouse monoclonal clone and MF6 small molecule (absorbance value)

[0278]

[0279] Table 5 Binding results of anti-MF6 rabbit monoclonal antibody and MF6 small molecule (absorbance value)

[0280]

[0281] Example 4 Application of anti-MWC-1 mouse monoclonal antibody and anti-MF6 rabbit monoclonal antibody in ADC detection

[0282] 1. Test materials

[0283] Table 6 Material information

[0284]

[0285] In the above materials, Trastuzumab ADC-DAR1, DAR2, and DAR3 represent ADCs with 1, 2, and 3 MF6 toxins attached to each antibody molecule. The preparation method is to use cathepsin B to partially hydrolyze Trastuzumab ADC (DAR4) to obtain a mixture with different DAR values, and then separate and collect the components with different DAR values ​​by preparative hydrophobic interaction liquid phase separation.

[0286] 2. Main instruments and equipment

[0287] Table 7 Instruments and equipment

[0288] Name of instrument model Manufacturer Microplate Reader Sunrise Tecan

[0289] 3. Test methods

[0290] 3.1 Test steps

[0291] 3.1.1 Coating: MWC-1 mouse monoclonal antibody and MF6 rabbit monoclonal antibody were coated at 4°C overnight, with a coating concentration of 1 μg / mL, 100 μl / well;

[0292] 3.1.2 Blocking: Wash the plate 3 times with PBST, pat dry, add 3% BSA / PBST solution, and incubate at room temperature for 2 h;

[0293] 3.1.3 Sample dilution and addition:

[0294] Standard dilution: Trastuzumab ADC (intact ADC molecule, DAR value of 4, Trastuzumab antibody end is a human antibody) was diluted to 10 ng / ml with 1% BSA / PBST as the starting concentration, and then serially diluted with 1% BSA / PBST as the zero point.

[0295] Sample dilution: Dilute the samples of Trastuzumab ADC with different DAR values ​​to 5 ng / ml (HPC) and 1 ng / ml (LPC) with 1% BSA / PBST, add the above samples to the ELISA plate at 100 μl / well, set up duplicate wells, and incubate at room temperature for 2 h;

[0296] After washing the plate three times with PBST and patting it dry, the above samples were added to the ELISA plate at 100 μl / well and incubated at room temperature for 2 h;

[0297] 3.1.4 Add detection antibody: Wash the plate 4 times with PBST and pat dry. Dilute goat anti-human light chain antibody (HRP) with 1% BSA / PBST at 1:20000, add 100 μl / well to the corresponding ELISA plate, and incubate at room temperature for 1 hour;

[0298] 3.1.5 Color development: Wash the plate three times with PBST and pat dry. Add TMB substrate to the ELISA plate at 100 μl / well and incubate at room temperature in the dark for about 10 min.

[0299] 3.1.6 Termination: Add 100 μl / well of 1M H3PO4 to terminate the reaction;

[0300] 3.1.7 Plate reading: After terminating the color development reaction, use 650nm as the reference wavelength and read the OD value at 450nm.

[0301] 3.2 Test results

[0302] The results are shown in Table 8 and Figure 1 As shown in the figure, both anti-MWC-1 mouse monoclonal antibody (S-22-11, S-140-9) and anti-MF6 rabbit monoclonal antibody (45G1-1) can detect the concentration of Trastuzumab ADC, among which anti-MWC-1 mouse monoclonal antibody (S-140-9) and anti-MF6 rabbit monoclonal antibody (45G1-1) have higher detection ability for low DAR value ADC, and the detection rates are within the range of 80.0-120.0% of the theoretical value, which is within the acceptable range.

[0303] Table 8 Detection results of small molecule antibodies against Trastuzumab ADC with different DAR values

[0304]

[0305]

[0306] Example 5 Application of anti-MF6 monoclonal antibody in the stability of MF6 toxin-binding ADC in human plasma and monkey plasma

[0307] 1. Test materials

[0308] Table 9 Material information

[0309]

[0310] 2. Main instruments and equipment

[0311] Table 10 Instruments and Equipment

[0312] Name of instrument model serial number factory Multifunctional ELISA reader SpectramaxM5 02-IN010 Molecular Devices

[0313] 3. Sample Preparation

[0314] 100% pooled human plasma (PHP) and 100% pooled monkey plasma (PMP) were filtered with a 0.22 μm filter membrane to prepare human plasma and monkey plasma samples containing 200 μg / ml (HPC) and 10 μg / ml (LPC) of Trastuzumab ADC, respectively. The samples were placed at 37°C and samples were taken for testing at 0, 12 h, 1 day, 3 days, 5 days, 7 days, 10 days and 14 days.

[0315] 4. Experimental steps

[0316] 4.1 Coating: dilute anti-MWC-1 mouse monoclonal antibody (S-22-11) and anti-MF6 rabbit monoclonal antibody (45G1-1) to 1 μg / mL with coating solution, add 100 μl / well to the corresponding ELISA plate, and incubate at 2-8°C overnight;

[0317] 4.2 Blocking: Pat the ELISA plate dry, rinse the ELISA plate 3 times with 200 μl / well PBST; Pat the ELISA plate dry, add 200 μl / well 3% BSA / PBST solution, and incubate at room temperature for 2 h;

[0318] 4.3 Sample addition: Pat the blocked ELISA plate dry and rinse the plate three times with Washing buffer, 200 μl / well.

[0319] Standard dilution: Trastuzumab ADC was diluted to 10 ng / ml with 2% pooled human plasma (PHP) and 2% pooled monkey plasma (PMP) as the starting concentration, and a 2-fold serial dilution was performed for a total of 8 points, with 2% PHP and 2% PMP as the 0 point.

[0320] Quality control sample dilution: The standard was diluted with 2% PHP and 2% PMP as quality control samples, respectively, ULOQ: 10 ng / ml, HQC: 8 ng / ml, MQC: 2 ng / ml, LQC: 0.4 ng / ml, LLOQ: 0.156 ng / ml.

[0321] Sample dilution: High concentration samples (HPC) and low concentration samples (LPC) were first diluted 50 times with 1% BSA / PBST, and then further diluted to 2 ng / ml with corresponding 2% PHP and 2% PMP.

[0322] The above samples were added to the ELISA plate at 100 μl / well, with duplicate wells, and incubated at room temperature for 2 h;

[0323] 4.4 Add detection antibody: Pat the ELISA plate dry after reaction, and wash the plate 6 times with Washing buffer, 200μl / well. Dilute anti-Trastuzumab mouse monoclonal antibody-Biotin to 0.2μg / ml with 1% BSA / PBST, add 100μl / well to the ELISA plate, and incubate at room temperature for 1h;

[0324] 4.5 Add Streptavidin-HRP: Pat the plate dry after the reaction, and wash the plate 6 times with Washing buffer, 200μl / well. Dilute Streptavidin-HRP with 1% BSA / PBST at 1:50000, add 100μl / well to the plate, and incubate at room temperature for 1h;

[0325] 4.6 Color development: Pat the ELISA plate dry after the reaction, and wash the plate 6 times with Washing buffer, 200 μl / well. Add TMB substrate to the ELISA plate at 100 μl / well, and incubate at room temperature in the dark for about 10 minutes;

[0326] 4.7 Termination: Add 100 μl / well of 1M H3PO4 to terminate the reaction;

[0327] 4.8 Plate reading: After terminating the color development reaction, use 650nm as the reference wavelength and read the OD value at 450nm.

[0328] 5 Test results

[0329] The stability of Trastuzumab ADC in human plasma and monkey plasma at 37°C was tested using anti-MWC-1 mouse monoclonal antibody and anti-MF6 rabbit monoclonal antibody as capture antibodies, respectively. The results are shown in Tables 11 and 12. The curve of the ratio of ADC measured concentration to zero-point concentration over time is shown in Figure 2-Figure 3 shown.

[0330] The results showed that the ratio of the measured ADC concentration of high and low concentration samples to the 0-point concentration in human plasma and monkey plasma at 37°C gradually decreased with time. Trastuzumab ADC in human plasma was relatively more unstable, and small molecules shed faster. The stability study of ADC drugs in plasma in vitro is an important data for determining whether the drug can remain stable in the blood. It is inevitable that ADC drugs shed some toxins in the blood, so a series of products with low DAR values ​​will be produced. If the antitoxin antibody used in the evaluation of in vitro plasma stability cannot accurately detect low DAR value ADC samples, then the concentration of ADC in plasma will be "underestimated" and the drug stability cannot be judged. We have verified that mouse monoclonal antibody (S-22-11) and rabbit monoclonal antibody (45G1-1) have good detection rates for Trastuzumab ADCs with different DAR values. Therefore, when used in in vitro plasma stability testing, it can effectively cover low DAR value samples and more objectively evaluate the stability of ADC in plasma.

[0331] Table 11 MF6 conjugated ADC drug concentration-time variation standard curve data (S-22-11)

[0332]

[0333] Table 12 MF6 conjugated ADC drug concentration-time variation standard curve data (45G1-1)

[0334]

[0335] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A monoclonal antibody, characterized in that The three CDR regions of the light chain have the amino acid sequences shown in any one of SEQ ID NOs: 1 to 9 respectively; The three CDR regions of the heavy chain have the amino acid sequences shown in any one of SEQ ID NOs: 10 to 18 respectively; Preferably, The amino acid sequences of its light chain CDR1 to 3 are shown in SEQ ID NOs: 1, 4, and 7, respectively, and the amino acid sequences of its heavy chain CDR1 to 3 are shown in SEQ ID NOs: 10, 13, and 16, respectively; or the amino acid sequences of its light chain CDR1 to 3 are shown in SEQ ID NOs: 2, 5, and 8, respectively, and the amino acid sequences of its heavy chain CDR1 to 3 are shown in SEQ ID NOs: 11, 14, and 17, respectively; Or the amino acid sequences of its light chain CDR1-3 are shown in SEQ ID NOs: 3, 6, and 9, respectively, and the amino acid sequences of its heavy chain CDR1-3 are shown in SEQ ID NOs: 12, 15, and 18, respectively.

2. The monoclonal antibody according to claim 1, characterized in that The four FR regions of the light chain have the amino acid sequence shown in any one of SEQ ID NOs: 19 to 30 respectively; The four FR regions of the heavy chain have an amino acid sequence as shown in any one of SEQ ID NOs: 31 to 42; Preferably, The amino acid sequences of the light chain FR1 to 4 are shown in SEQ ID NOs: 19, 22, 25, and 28, respectively, and the amino acid sequences of the heavy chain FR1 to 4 are shown in SEQ ID NOs: 31, 34, 37, and 40, respectively; or the amino acid sequences of its light chain FR1-4 are shown in SEQ ID NOs: 20, 23, 26, 29, and its heavy chain FR1-4 are shown in SEQ ID NOs: 32, 35, 38, 41, respectively; Or the amino acid sequences of its light chain FR1-4 are shown in SEQ ID NOs: 21, 24, 27, 30, and its heavy chain FR1-4 are shown in SEQ ID NOs: 33, 36, 39, 42, respectively.

3. The monoclonal antibody according to claim 1 or 2, characterized in that Its light chain variable region has the amino acid sequence shown in SEQ ID NOs: 43-45; Its heavy chain variable region has the amino acid sequence shown in SEQ ID NOs: 46-48; Preferably, Its light chain variable region has the amino acid sequence shown in SEQ ID NO:43, and its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:46; Alternatively, its light chain variable region has the amino acid sequence shown in SEQ ID NO:44, and its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:47; Alternatively, its light chain variable region has the amino acid sequence shown in SEQ ID NO:45, and its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:

48.

4. The monoclonal antibody according to any one of claims 1 to 3, characterized in that It also includes a constant region, wherein the constant region of the heavy chain is mouse IgG or rabbit IgG, and the constant region of the light chain is of κ type.

5. Biological materials, including at least one of the following I) to V): I), a nucleic acid encoding the monoclonal antibody according to any one of claims 1 to 4; II), an expression vector comprising the nucleic acid described in I); III), a host, the genome of which is integrated with the nucleic acid described in I); or transfected or transformed with the expression vector described in II); IV), a labeled antibody, which is a chemically labeled or biologically labeled monoclonal antibody according to any one of claims 1 to 4; V) A conjugate prepared by coupling the monoclonal antibody according to any one of claims 1 to 4 or the labeled antibody according to IV) with a solid medium or a semi-solid medium.

6. A method for preparing the monoclonal antibody according to any one of claims 1 to 4, comprising: Cultivating the host described in claim 5 and inducing the expression of the monoclonal antibody.

7. Use of any of the following in the preparation of a detection reagent for a complex of a camptothecin compound and a protein; I), the monoclonal antibody according to any one of claims 1 to 4; II), the labeled antibody as described in claim 5; III), the conjugate described in claim 5; Preferably, in the complex of camptothecin compound and protein, the camptothecin compound is MF6 or MWC-1, and the protein is BSA or an antibody targeting HER2.

8. A detection reagent for a complex of camptothecin compounds and proteins, characterized in that: Includes any of the following: I), the monoclonal antibody according to any one of claims 1 to 4; II), the labeled antibody as described in claim 5; III), the conjugate described in claim 5; Preferably, the detection reagent further includes an ELISA plate, a detection antibody, a blocking solution, a sample diluent, a flushing solution and a color developing solution; Wherein, the detection antibody is a goat anti-human antibody labeled with HRP or a goat anti-rabbit antibody labeled with HRP; The blocking solution is PBST buffer containing 3wt% BSA; The sample diluent is PBST buffer containing 1 wt% BSA; The flushing solution is PBST buffer; The color developing solution is TMB solution.

9. A method for detecting a complex of a camptothecin compound and a protein, comprising detecting a sample with the detection reagent according to claim 8.

10. The detection method according to claim 9, characterized in that: The detection includes the detection of the content of camptothecin compound-antibody binding drug in plasma and / or the detection of the stability of camptothecin compound-antibody binding drug.

Citation Information

Patent Citations

  • RNA-coded antibody

    EP2101823B1